Transforming therapeutic windows in Nephrology
Our drive
Identify therapeutics with an accelerated discovery-to-clinic process by focusing in drug re-development to pharmacologically compensate genetic deficiencies in rare renal diseases.
Medetia & C'IL-LICO
In 2019, Medetia integrates the RHU (« Recherche Hospitalo-Universitaire en santé » ) consortium C’IL-LICO, as industrial partner.
The C’IL-LICO project proposes a new approach for the management of a group of rare and serious genetic diseases, ciliopathies that cause the deterioration of renal function and lead to end-stage renal failure. The project is led by Prof. Stanislas Lyonnet, director of the Imagine Hospital-University Institute (Paris).
Our Ecosystem
By mid 2019, Medetia is expected to formalised its partnership with Imagine Imagine Institute.
Imagine is a research and innovative healthcare institute of a new type, bringing together researchers, doctors and patients, with a common goal: to cure genetic diseases.
